Talquetamab Outcomes Studied at Tampa Cancer Center
Researchers analyzed drug effectiveness in patients previously excluded from registrational clinical trials.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust evidence from real-world retrospective studies when making decisions about your own medical treatments?
At the 2026 SOHO Annual Meeting, researchers presented findings on the use of talquetamab in patients who did not meet MonumenTAL-1 trial eligibility criteria. The study, conducted at Moffitt Cancer Center, tracked outcomes for 95 patients who had undergone a median of seven prior lines of therapy.
Why it matters
The study assessed the efficacy of talquetamab in real-world patients excluded from pivotal registrational trials, reflecting its growing role as T-cell-redirecting therapies move into earlier treatment phases.
A retrospective study of 95 patients found median overall survival reached 22.5 months for those ineligible for trial criteria, compared to 11.2 months for trial-eligible patients. Cytokine release syndrome occurred in 40.0 percent of the cohort.
The players
Moffitt Cancer Center
This Tampa-based facility is a major National Cancer Institute-designated comprehensive cancer center conducting clinical and basic research.
The details
Investigators at Moffitt Cancer Center retrospectively adjudicated trial eligibility using published standards to assess 95 patients treated between May 2023 and November 2025. With a median patient age of 67, researchers utilized Kaplan-Meier methods and log-rank tests to measure survival and response efficacy following therapy.
Timeline
The FDA granted accelerated approval to talquetamab in August 2023.
The study patient treatment period at Moffitt Cancer Center occurred from May 2023 to November 2025.
Findings were presented at the SOHO Annual Meeting on September 9-12, 2026.
Health Landscape
The research findings extend the clinical outcomes previously established by the MonumenTAL-1 trial to a broader, real-world patient population. This move reflects a wider trend in oncology where academic centers validate treatment efficacy for patients who fall outside the rigid constraints of original registrational studies.
This study offers potential insights for patients who may not qualify for standard clinical trials but require access to T-cell-redirecting therapies. Clinicians may use this data to better manage the 40 percent incidence rate of cytokine release syndrome through targeted care and monitoring protocols.
The takeaway
The study suggests that talquetamab provides meaningful survival benefits even for patients previously excluded from early clinical trials. These results highlight the importance of real-world evidence in expanding treatment access for complex cancer cases.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust evidence from real-world retrospective studies when making decisions about your own medical treatments?
